Category: Finance | Title: Paige AI Stock, Valuation, Funding, and Latest Company Data | Tag: Paige AI | Meta Description: Paige AI stock valuation, funding rounds, financials, and company data explained with latest public information and investor insights...
Paige AI Company Overview and Current Valuation
Paige is a digital pathology and AI company focused on cancer diagnostics. The company develops machine learning models trained on large pathology datasets to assist clinical workflows. Paige has raised significant venture capital and is valued at several billion dollars based on recent private funding rounds and secondary market data.
Paige's valuation reflects its proprietary data assets, regulatory clearances, and partnerships with major pathology labs and pharmaceutical companies. Investors include leading healthcare and technology-focused funds. The company positions itself at the intersection of healthcare AI and precision medicine, targeting both clinical and research applications.
Paige AI Funding, Investors, and Financial Performance
Paige has completed multiple funding rounds, with its most recent major raise bringing in hundreds of millions of dollars from institutional investors. The company's capitalization is estimated based on private market transactions and secondary share sales, with valuations influenced by growth in digital pathology adoption and AI regulatory approvals.
Paige's revenue model includes software licensing, cloud-based AI services, and partnerships with diagnostic laboratories. Financial details are not fully public because Paige remains a private company, but reported metrics show strong growth in customer deployments and data volume processed by its AI systems.
Paige AI Technology, Market Position, and Competitive Landscape
Paige's core technology is a deep learning platform trained on gigapixel pathology images to detect cancer and other diseases. The company holds regulatory clearances for specific AI-powered diagnostic tools, which are considered key milestones for commercial adoption in clinical settings.
Paige competes with other AI pathology companies and large technology firms entering healthcare AI. The market for AI in pathology is growing as hospitals and labs adopt digital slide scanning and automated analysis tools. Paige's first-mover advantage in data scale and regulatory approvals is cited as a competitive strength.